Implanet’s JAZZ Cap® technology has been patented in Japan.
Primarily developed for the treatment of adult degenerative disorders, JAZZ Cap protects screw fixation in poor quality bone. The technology is an alternative to cement-augmented pedicle screws, and has received CE Mark approval and FDA 510(k) clearance.
This latest protection further expands Implanet’s patent portfolio, which includes 31 patents specifically devoted to the JAZZ™ platform.
Ludovic Lastennet, CEO of Implanet, said, “Japan represents the world’s third largest market in the treatment of spinal disorders after the United States and China. We felt that it was essential to protect this new generation of Jazz Cap products in this high potential market. Being granted this patent is a major step for the development of our solution, which is now covered in the United States, Europe and Japan, and also provides us with a major opportunity on the Japanese degenerative spine surgery market.”
Implanet's JAZZ Cap® technology has been patented in Japan.
Primarily developed for the treatment of adult degenerative disorders, JAZZ Cap protects screw fixation in poor quality bone. The technology is an alternative to cement-augmented pedicle screws, and has received CE Mark approval and FDA 510(k) clearance.
Implanet’s JAZZ Cap® technology has been patented in Japan.
Primarily developed for the treatment of adult degenerative disorders, JAZZ Cap protects screw fixation in poor quality bone. The technology is an alternative to cement-augmented pedicle screws, and has received CE Mark approval and FDA 510(k) clearance.
This latest protection further expands Implanet’s patent portfolio, which includes 31 patents specifically devoted to the JAZZ™ platform.
Ludovic Lastennet, CEO of Implanet, said, “Japan represents the world’s third largest market in the treatment of spinal disorders after the United States and China. We felt that it was essential to protect this new generation of Jazz Cap products in this high potential market. Being granted this patent is a major step for the development of our solution, which is now covered in the United States, Europe and Japan, and also provides us with a major opportunity on the Japanese degenerative spine surgery market.”
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
Copy to clipboard 
